2-(1-methyl-1H-indol-2-yl)prop-2-enoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(1-methyl-1H-indol-2-yl)prop-2-enoic acid
• 英文别名: 2-(1-methylindol-2-yl)prop-2-enoic acid
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.22
• InChiKey: PMSNVEROLJHCCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• TREATMENT OF MELANOMA AND LUNG CARCINOMA USING A SMAD3 INHIBITOR
  申请人：The Chinese University of Hong Kong

  公开号：EP3320906A1

  公开（公告）日：2018-05-16

  The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of Smad3. Further provided are compositions and kits useful for treating cancer by way of inhibiting Smad3 signaling.

  本发明在于发现 Smad3 是 TGF-β 信号传导的关键下游介质，在癌症的发生和发展中起着关键作用。因此，本申请提供了一种通过抑制 Smad3 信号传导治疗癌症的新方法，例如通过施用 Smad3 的抑制剂 SIS3。本申请还提供了通过抑制 Smad3 信号转导治疗癌症的组合物和试剂盒。
• TREATMENT OF LUNG CANCER USING THE SMAD3 INHIBITOR SIS3
  申请人：The Chinese University Of Hong Kong

  公开号：EP2911661B1

  公开（公告）日：2017-11-29
• TREATMENT OF CANCER USING A SMAD3 INHIBITOR
  申请人：The Chinese University Of Hong Kong

  公开号：EP2911661A1

  公开（公告）日：2015-09-02
• TREATMENT OF CANCER USING SMAD3 INHIBITOR
  申请人：THE CHINESE UNIVERSITY OF HONG KONG

  公开号：US20140120116A1

  公开（公告）日：2014-05-01

  The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of Smad3. Further provided are compositions and kits useful for treating cancer by way of inhibiting Smad3 signaling.
• [EN] TREATMENT OF CANCER USING A SMAD3 INHIBITOR<br/>[FR] TRAITEMENT DU CANCER À L'AIDE D'UN INHIBITEUR DE SMAD3
  申请人：UNIV HONG KONG CHINESE

  公开号：WO2014063659A1

  公开（公告）日：2014-05-01

  The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of Smad3. Further provided are compositions and kits useful for treating cancer by way of inhibiting Smad3 signaling.